1058705-94-4

Basic information

• Product Name: N-tert-butoxycarbonyl-2-amino-8-nonenoic acid dicyclohexylamine salt
• Synonyms: N-tert-butoxycarbonyl-2-amino-8-nonenoic acid dicyclohexylamine salt
• CAS NO: 1058705-94-4
• Molecular Weight: 452.678
• Mol File: 1058705-94-4.mol

Chemical Properties

• Melting Point: 82-84 °C(Solv: heptane (142-82-5))
• CAS DataBase Reference: N-tert-butoxycarbonyl-2-amino-8-nonenoic acid dicyclohexylamine salt(CAS DataBase Reference)
• NIST Chemistry Reference: N-tert-butoxycarbonyl-2-amino-8-nonenoic acid dicyclohexylamine salt(1058705-94-4)
• EPA Substance Registry System: N-tert-butoxycarbonyl-2-amino-8-nonenoic acid dicyclohexylamine salt(1058705-94-4)

Safety Data

• Hazardous Substances Data: 1058705-94-4(Hazardous Substances Data)

Upstream product

• 924307-76-6 (S)-2-amino-8-nonenoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 101-83-7 N-cyclohexyl-cyclohexanamine 
• 4117-09-3 7-bromo-hept-1-ene 
• 924309-93-3 (±)-2-acetamido-8-nonenoic acid 
• 915314-56-6 (R)-1-chloronon-8-en-2-ol 
• 300831-21-4 (S)-2-(tert-butoxycarbonylamino)non-8-enoic acid 

Downstream Products

• 1565779-15-8 C₃₇H₄₄FN₃O₆ 
• 300831-21-4 (S)-2-(tert-butoxycarbonylamino)non-8-enoic acid 

Relevant articles and documents

Synthetic method of optical activity N-tert-butoxycarbonyl-2-amino-8-nonenoic dicyclohexylamine salt

The invention provides a method for preparing optical activity N-tert-butoxycarbonyl-2-amino-8-nonenoic dicyclohexylamine salt, wherein X is halogen. The method realizes configuration inversion through a Mitsunobu reaction, and can obtain an optical purit

COMPOUNDS AS HEPATITIS C INHIBITORS AND USES THEREOF IN MEDICINE

Provided herein are compounds as hepatitis C inhibitors and uses thereof in medicine. Specifically, provided herein is a compound of Formula (I) or a stereoisomer, a tautomer, an enantiomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or hepatitis C diseases. Also provided herein are a pharmaceutically acceptable composition containing such compound and a method of treating HCV infection or hepatitis C diseases comprising administering the compound or pharmaceutical composition thereof disclosed herein.